Healthcare provider profile · identity verified

Sarojini Devi Schorling, MD

Family Practice · FRESNO, CA · NPI 1841590320

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	395	161
Lisinopril	Lisinopril	289	108
Levothyroxine Sodium	Levothyroxine Sodium	272	101
Losartan Potassium	Losartan Potassium	271	103
Amlodipine Besylate	Amlodipine Besylate	201	86
Hydrochlorothiazide	Hydrochlorothiazide	188	65
Metformin Hcl	Metformin Hcl	179	66
Albuterol Sulfate Hfa	Albuterol Sulfate	149	77
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	139	47
Omeprazole	Omeprazole	138	61
Furosemide	Furosemide	133	56
Simvastatin	Simvastatin	121	47
Famotidine	Famotidine	117	51
Atenolol	Atenolol	115	48
Glipizide	Glipizide	111	41
Gabapentin	Gabapentin	110	53
Pantoprazole Sodium	Pantoprazole Sodium	102	44
Metoprolol Tartrate	Metoprolol Tartrate	97	42
Montelukast Sodium	Montelukast Sodium	93	40
Fluticasone Propionate	Fluticasone Propionate	90	44
Ibuprofen	Ibuprofen	90	36
Tramadol Hcl	Tramadol Hcl	88	38
Cephalexin	Cephalexin	87	73
Potassium Chloride	Potassium Chloride	82	34
Prednisone	Prednisone	71	58
Pravastatin Sodium	Pravastatin Sodium	69	26
Hydralazine Hcl	Hydralazine Hcl	68	24
Alvesco	Ciclesonide	67	29
Tamsulosin Hcl	Tamsulosin Hcl	65	29
Allopurinol	Allopurinol	62	24
Tizanidine Hcl	Tizanidine Hcl	62	33
Terazosin Hcl	Terazosin Hcl	58	19
Alendronate Sodium	Alendronate Sodium	57	28
Fluoxetine Hcl	Fluoxetine Hcl	55	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	55	20
Doxycycline Monohydrate	Doxycycline Monohydrate	54	47
Ozempic	Semaglutide	51	19
Trospium Chloride	Trospium Chloride	51	21
Nifedipine Er	Nifedipine	50	16
Alprazolam	Alprazolam	48	14
Meloxicam	Meloxicam	47	14
Ondansetron Odt	Ondansetron	47	16
Triamcinolone Acetonide	Triamcinolone Acetonide	46	30
Metoprolol Succinate	Metoprolol Succinate	45	25
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	45	suppressed
Trazodone Hcl	Trazodone Hcl	45	25
Wixela Inhub	Fluticasone Propion/Salmeterol	45	14
Hydrocortisone	Hydrocortisone	41	18
Humulin N	Insulin Nph Human Isophane	38	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	37	14
Carvedilol	Carvedilol	37	11
Metformin Hcl Er	Metformin Hcl	37	17
Naproxen	Naproxen	37	14
Rosuvastatin Calcium	Rosuvastatin Calcium	37	17
Fenofibrate	Fenofibrate	36	13
Sertraline Hcl	Sertraline Hcl	36	12
Celecoxib	Celecoxib	35	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	35	15
Lactulose	Lactulose	35	11
Jardiance	Empagliflozin	34	15
Pioglitazone Hcl	Pioglitazone Hcl	34	15
Amoxicillin	Amoxicillin	31	27
Duloxetine Hcl	Duloxetine Hcl	30	12
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	12
Humulin R	Insulin Regular, Human	29	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	29	14
Glipizide Er	Glipizide	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	27	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	25	suppressed
Estradiol	Estradiol	24	14
Finasteride	Finasteride	24	suppressed
Lovastatin	Lovastatin	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	17
Pradaxa	Dabigatran Etexilate Mesylate	22	11
Temazepam	Temazepam	21	suppressed
Fluocinonide	Fluocinonide	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	19	suppressed
Acyclovir	Acyclovir	18	12
Nabumetone	Nabumetone	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	17	suppressed
Lorazepam	Lorazepam	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Ketoconazole	Ketoconazole	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Colchicine	Colchicine	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	13	12
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error